Figure 1. Recall as a function of precision for PhenoPred (solid blue line) against the uniformly random predictor (dotted red line).

METHODS
For each protein p, we constructed three sets of features for predicting disease associations: (i) PPI-DO features were constructed based on the distribution of shortest distances from p to other proteins in the PPI network known to be associated with specific disease terms; (ii) PPI-GO features were constructed in a similar way, but based on the shortest distances to other proteins known to be associated with specific GO terms; (iii) SPP-GO features encode various sequence, physicochemical, and other predicted properties of the protein as well as its GO terms.
To construct PPI-DO (and equivalently PPI-GO) features, we first computed the shortest distances between all pairs of proteins in the PPI network. For each combination of (p, d), where d is a disease term, we find the distribution of shortest distances from protein p to all proteins known to be associated with d, or simply the distribution of distances to disease d. In addition, we encoded fractions of proteins associated with disease d amongst p's level-t neighbors (t = 1, 2…). Our assumption is that a protein p associated with disease d is more likely to share the distribution of distances to the DO terms with the proteins associated with d than the remaining proteins. The sequence-based and functional features (SPP-GO) were constructed based on (i) the real-valued vector data that is obtained for each physicochemical or predicted property and (ii) binary encoding of the known GO annotation and PROSITE matches. The real-valued data representation of a protein can be easily obtained by predicting its properties, e.g. secondary structure or intrinsic disorder, which effectively map an amino acid sequence into a realvalued vector (signal) of the same length. If we consider s to be such a property signal corresponding to protein p, then a set of features was generated based on the following: (i) the length of s; (ii) the mean and standard deviation of s; (iii) percentage of s that is above n-th percentile of the range of s (for various n) and (iv) the number of times each signal crosses these thresholds. We used the following properties: predictions of helix, sheet, coil, accessible surface area (ASA) and relative ASA as predicted by PHD, hydrophobic moment, flexibility predictions and predictions of intrinsically disordered protein regions. In addition, we calculated amino acid composition of each protein, as well as the number, orientation, and separation between predicted transmembrane helices by TMHMM. Physicochemical properties included aromatic content and charge. Finally, the GO and PROSITE information was encoded using a binary representation. The rationale for the use of property signals is that certain classes of disease-associated proteins have strong biases in their physicochemical properties. For example, it has been shown that cancer-related proteins and proteins involved in cardiovascular disease are significantly enriched in intrinsic disorder. All types of information are incorporated through a supervised framework using two layers of support vector machines. The first layer was built for each individual type of encoding (PPI-DO, PPI-DO, SPP-GO), while the second layer is simply a weighted average of the outputs of the first layer.
RESULTS
The predictor accuracy was evaluated using cross-validation on 422 DO terms for which 10 or more associated proteins were available. We evaluated all three individual models described above and a combined model that integrates the individual models (PhenoPred). Precision-recall curve for PhenoPred is shown in Figure 1 , and it was shown that it achieved higher accuracy than any of the individual models, indicating usefulness of all lines of experimental evidence. 1 The average area under the ROC curve (AUC) over the 422 DO terms was 73.1%, however, it includes terms on which prediction results were nearly random (42 terms had AUC below 60%). In addition, the predictor was manually evaluated on several disease terms, of which we will discuss some candidate proteins that will be interesting future targets.
